Literature DB >> 26309594

CD192 gene variant and susceptibility to cervical cancer: a meta analysis.

Yuying Chen1, Xinli Liu2, Min Chen3, Jian Shen3, Yanqi Lu3, Lei Yu4, Shouying Liu5.   

Abstract

BACKGROUND: Several molecular epidemiological studies have explored the association between G46295A variant of CD192 gene and cervical cancer susceptibility in distinct populations. However, the results are contradictory. To provide convincing evidence for the association, we performed the present meta-analysis incorporating all case-control studies. METHODS AND
FINDINGS: The Cochrane, Google Scholar and PubMed databases were systematically searched to identify the potentially relevant studies. Statistical analyses were performed using R software. Crude odds ratio (OR) was calculated to estimate the risk of cervical cancer. Five case-control studies were considered in the final analysis. Using the homozygous, heterogeneous, allele, dominant, and recessive model, we found the association between CD192 G46295A variant and cervical cancer was not statistically significant.
CONCLUSIONS: This meta-analysis shows that the CD192 G46295A variant may not confer genetic susceptibility towards cervical cancer.

Entities:  

Keywords:  CD192; cervical cancer; polymorphism

Year:  2015        PMID: 26309594      PMCID: PMC4538080     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  30 in total

Review 1.  The origin and function of tumor-associated macrophages.

Authors:  A Mantovani; B Bottazzi; F Colotta; S Sozzani; L Ruco
Journal:  Immunol Today       Date:  1992-07

2.  Chemokine-receptor polymorphisms: clarity or confusion for HIV-1 prognosis?

Authors:  P Garred
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

3.  Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma.

Authors:  Ana Coelho; Ana Matos; Raquel Catarino; Daniela Pinto; Deolinda Pereira; Carlos Lopes; Rui Medeiros
Journal:  Gynecol Oncol       Date:  2005-03       Impact factor: 5.482

4.  Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma.

Authors:  A Sica; A Saccani; B Bottazzi; S Bernasconi; P Allavena; B Gaetano; F Fei; G LaRosa; C Scotton; F Balkwill; A Mantovani
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  IL-2-regulated expression of the monocyte chemotactic protein-1 receptor (CCR2) in human NK cells: characterization of a predominant 3.4-kilobase transcript containing CCR2B and CCR2A sequences.

Authors:  N Polentarutti; P Allavena; G Bianchi; G Giardina; A Basile; S Sozzani; A Mantovani; M Introna
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

Review 7.  Chemokines in cancer.

Authors:  Alain P Vicari; Christophe Caux
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

8.  Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients.

Authors:  Biying Zheng; Fredrik Wiklund; Baback Gharizadeh; Mehdi Sadat; Giovanni Gambelunghe; Göran Hallmans; Joakim Dillner; Keng-Ling Wallin; Mehran Ghaderi
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

9.  Role of eotaxin-1 signaling in ovarian cancer.

Authors:  Vera Levina; Brian M Nolen; Adele M Marrangoni; Peng Cheng; Jeffrey R Marks; Miroslaw J Szczepanski; Marta E Szajnik; Elieser Gorelik; Anna E Lokshin
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.